Probi AB (Probi), a subsidiary of Symrise AG, focuses on the research, development, and production of probiotics. It identifies patented and effective probiotics and licenses them to international companies for use in nutritional products, such as foodstuffs and dietary supplements. Probi's business revolves around the development and production of probiotics, which are live microorganisms that confer health benefits when consumed in adequate amounts. The company's products are available in various forms, including powders, capsules, tablets, and foods. The company offers products under Consumer Healthcare and Functional Food divisions. The Consumer Healthcare division develops, markets and sells probiotics in partnership with pharmaceutical companies and other companies specialized in probiotics and self-care products, through Probi’s proprietary brand and those of its partners. It offers probiotics in different forms, including freeze-dried culture, suitable for dry applications and drinks; frozen pellets, suitable for chilled drinks and dairy products; frozen cultures for aseptic filling, suitable for milk and juices; and dietary supplements, available in capsules and sachets, as well as flavored tablets. The Functional Food division offers probiotic concepts for a number of common foodstuffs, including fruit drinks, yogurt, fruit shots, recovery drinks, ice creams and others. The company offers an array of products, covering areas such as digestive health, immunity, iron absorption, bone health, and solutions for different demographics, including women, children, and seniors. The company's products are sold in more than 40 markets worldwide. Probi operates its own fermentation, formulation, and production processes in Good Manufacturing Practice (GMP) certified facilities. The company also holds nearly 400 approved patents.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Probi has undertaken significant R&D initiatives, focusing on the development of probiotic strains and solutions. The company has published numerous scientific articles and clinical trials, particularly on the LP299V strain, and has expanded its research into areas such as gut-brain health, cognitive function, and mental wellness. The R&D unit of Probi AB is responsible for conducting state-of-the-art preclinical and clinical studies to evaluate the health effects of the company's probiotics. The R&D team is also involved in developing new products and supporting regulatory compliance. It holds more than 400 granted patents,351 registered patents and products available in more than 40 markets. The company collaborates with various international research groups and academic institutions, such as the Department of Internal Medicine and Clinical Nutrition at the University of Gothenburg, the Microbial Ecology Group at the University of Aberdeen, and the Host-Microbe Interactomics Group at Wageningen University & Research. These collaborations focus on characterizing bacterial isolates, investigating probiotic effects, and developing novel vaccines.